Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 2/20 | 0.41 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | KIF18A | Q8NI77 | 11/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CENPE | Q02224 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24319703 | 0.84 | PARG (0.43) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL8112810 | 0.81 | SLC40A1 (0.49) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL9378913 | 0.79 | KIF18A (0.47) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL22120881 | 0.79 | NSD2 (0.49) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL8322949 | 0.79 | MAPT (0.45) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL245099 | 0.75 | DHFR (0.41) | SMN1; SMN2KDM4EHPGDALDH1A1 | |
| SCHEMBL29703778 | 0.74 | CA12 (0.43) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL30253017 | 0.74 | LOX (0.41) | SMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL1404067 | 0.74 | LOX (0.41) | SMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL2400693 | 0.73 | MAPT (0.54) | MAPTSMN1; SMN2KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12441736-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3898592-B1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220002311-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3898592-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897855-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132653-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132653-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132651-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20100197711-A1 | BENZOTHIAZOLE COMPOUNDS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-08-05 | — | — | US | disclosed |
| EP-2193127-A1 | BENZOTHIAZOLE COMPOUNDS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009039553-A1 | BENZOTHIAZOLE COMPOUNDS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197711-A1 | BENZOTHIAZOLE COMPOUNDS | BAD, BCL2, BAX | MAPT 1423/4885SMN1; SMN2 676/4885KDM4E 1470/4885 |
| US-12441736-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | MAPT 299/4885SMN1; SMN2 1204/4885KDM4E 1251/4885 |
| US-20220073504-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | MAPT 320/4885SMN1; SMN2 931/4885KDM4E 1625/4885 |
| US-20220002311-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | MAPT 299/4885SMN1; SMN2 1204/4885KDM4E 1251/4885 |
| US-12459932-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | MAPT 320/4885SMN1; SMN2 931/4885KDM4E 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.